An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c

Trial Profile

An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOM-1 HBL
  • Sponsors Intarcia Therapeutics
  • Most Recent Events

    • 04 Jan 2018 Results assessing efficacy and tolerability of a continuous delivery subcutaneous formulation of exenatide in patients with type 2 diabetes mellitus that is inadequately controlled with diet and exercise alone or in combination with oral antihyperglycaemics with high baseline HbA1c, were published in the Diabetes Care.
    • 19 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top